DOCSLIB.ORG

Stereopharmacology Research in Anaesthesiology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Stereopharmacology Research in Anaesthesiology COPYRIGHT AND USE OF THIS THESIS This thesis must be used in accordance with the provisions of the Copyright Act 1968. Reproduction of material protected by copyright may be an infringement of copyright and copyright owners may be entitled to take legal action against persons who infringe their copyright. Section 51 (2) of the Copyright Act permits an authorized officer of a university library or archives to provide a copy (by communication or otherwise) of an unpublished thesis kept in the library or archives, to a person who satisfies the authorized officer that he or she requires the reproduction for the purposes of research or study. The Copyright Act grants the creator of a work a number of moral rights, specifically the right of attribution, the right against false attribution and the right of integrity. You may infringe the author’s moral rights if you: - fail to acknowledge the author of this thesis if you quote sections from the work - attribute this thesis to another author - subject this thesis to derogatory treatment which may prejudice the author’s reputation For further information contact the University’s Copyright Service. sydney.edu.au/copyright Stereopharmacological research in anaesthesiology A thesis based on selected published works submitted in fulfilment of the requirements for the degree of Doctor of Medical Science of Sydney Medical School The University of Sydney by Laurence Edward Mather PhD, MSc, BSc ( NSW ), DipApplChem ( SydTechColl ), FANZCA, FRCA, FFPMANZCA (Hon) July 2015 “It will be at once admitted that the medical practitioner ought to be acquainted with the strength of the various compounds which he applies as remedial agents, and that he ought, if possible, to be able to regulate their potency.” (John Snow, On the inhalation of the vapour of ether. Lond Med Gaz IV: 498, 1847) “Dans les champs de l'observation le hasard ne favorise que les esprits préparés.” (Louis Pasteur, Lecture, University of Lille, December 7 1854) ii Summary This thesis is based on a theme of 63 selected publications taken from three of the author’s research programs (on local anaesthetic agents, intravenous anaesthetic agents, and nonsteroidal anti-inflammatory agents) and three individual drug projects (on halothane, ketamine and thalidomide). The publications have been selected to highlight the bearing of the chemistry of the drug, especially the stereochemistry, on some or other aspect of its pharmacology, of which 42 are designated Study (new experimental observations and knowledge), 18 are designated Review (syntheses of ideas from existent knowledge), and 3 are designated Patent (aspects of invention). The thesis is shaped by the narrative relating to the development of anaesthesia as first established by John Snow (1813-1858), and the contemporaneous stereochemical basis of pharmacology first described by Louis Pasteur (1822-1895). It presents each topic as a personal commentary identifying the historical context, rationale and outcome, and recognizing the work of collaborators and others at the institutions where the research was performed. The selected publications originate from research performed at the University of Sydney, the Flinders University of South Australia, and the University of Sheffield (UK), although prior work performed at the University of Washington (USA) also contributed. The ‘concepts and tools’ supporting the research are described in an historical context, corresponding to their evolution. In particular, the dual concepts of pharmacokinetics and pharmacodynamics underpin much of modern pharmacology and run throughout the theme of this thesis. Their investigation required reliable practical tools for physiological data acquisition, numerical data analysis, and drug assay methods, especially for the analytical resolution of chiral drugs used as racemates; however these tools evolved more slowly than the demands of the concepts. Eventually, when they were combined in appropriate ‘whole body’ pharmacological preparations, such as the author’s ‘multicannulated sheep preparation’ that allowed anatomically-correct and physiologically-sound assessment of drug disposition in association with quantitative measures of systemic drug effects, as well as with the ‘Stanford’ quantitative electroencephalography rodent model used for pharmacokinetics- pharmacodynamics, then real progress became possible, allowing greater insights into drugs used as racemates, such as those described in this thesis. The local anaesthetic program was instrumental in the registration and clinical introduction of two enantiopure substances, ropivacaine and levobupivacaine. The selections from the intravenous anaesthetic program focus on thiopentone and provide evidence of a greater margin of safety of R-thiopentone over the more potent S-thiopentone or the clinically-used racemate. Although the program led to a provisional patent for enantiopure thiopentone, clinical anaesthesia has since largely moved to using propofol which has a preferred pharmacokinetic profile to thiopentone. The selections from the nonsteroidal anti- inflammatory drug program focus on ketorolac, but produced inconclusive pharmacokinetic data; given the limited resources available, the program was changed to focus on (achiral) diclofenac. The ketamine project provided useful pharmacokinetic and pharmacodynamic data supporting the current clinical investigations of the pharmacologically preferred esketamine. The halothane project was designed to consider that differential enantiomeric disposition might influence halothane toxicity, but an enantiomeric difference was not found, and the project was terminated due to lack of funds. Finally, the thalidomide project documented that racemization precluded the use of a preferred enantiomer, but also produced a rationale for its use in future combined cancer chemotherapy developments. iii Table of Contents Stereopharmacological research in anaesthesiology Summary ii Table of Contents iii Foreword v Acknowledgements vi Thesis structure vii Declarations vii Selected publications viii 1. Concepts and tools 1 1.1 Basic medicinal chemical concepts 1 1.2 A glossary of basic stereochemical concepts 3 1.3 Essentials of experimental concepts and tools 7 1.4 Quantitation in anaesthesia – John Snow 8 1.5 Stereochemistry in pharmacology – Louis Pasteur 10 1.6 Stereopharmacology and anaesthesiology 12 1.7 Pharmacokinetics 15 1.8 Pharmacodynamics 17 1.9 Applied pharmacokinetics and pharmacodynamics 18 1.10 The ‘elephant in the laboratory’ 21 2. Translating chemistry into anaesthesiology – in stages 25 2.1 The University of Sydney (1966-1972) 25 2.2 The University of Washington (1972-1976) 27 2.3 Flinders Medical Centre (1976-1981) 31 2.4 The University of Massachusetts Medical Center (1981-1983) 37 2.5 Flinders Medical Centre (1983-1990) 37 2.6 The University of Sheffield (1988) 40 2.7 The University of Sydney (1991-2007) 41 3. Stereopharmacological research in anaesthesiology: the main theme 45 3.1 Introduction 45 3.11 Growing recognition of stereopharmacological issues 47 3.12 The main theme: stereopharmacological programs and projects 49 3.13 Basic concepts and experimental tools 49 Review 01. The rationale of our experimental techniques [110] 49 Reviews 02, 03 and 04. Early reviews of stereopharmacology [198,214,215] 50 3.2 Local anaesthetic agent program 51 3.21 Introduction 51 Reviews 05 and 06. Achiral aspects of local anaesthetic pharmacology [48,49] 51 3.22 Prilocaine 55 Study 01. Pharmacokinetics of prilocaine enantiomers in humans [197] 55 3.23 Bupivacaine 56 Study 02. Pharmacokinetics of mepivacaine and bupivacaine enantiomers in sheep [170] 57 Study 03. Bupivacaine pharmacokinetics with steady state infusion in sheep [177] 57 Study 04. Post-surgical plasma binding of bupivacaine enantiomers in sheep [188] 58 Study 05. Enantioselectivity of bupivacaine tissue distribution in sheep [190] 58 Study 06. Influence of i.v. infusion on bupivacaine pharmacokinetics in sheep [217] 58 Study 07. Bupivacaine pharmacokinetics with intercostal block in humans [218] 58 Study 08. Bupivacaine pharmacokinetics with epidural block in humans [246] 59 3.24 Levobupivacaine 59 Study 09. A new enantiospecific HPLC assay for the levobupivacaine program [250] 64 Study 10. Cardiovascular effects of i.v. bupivacaine and levobupivacaine [244] 64 Study 11. PK-PD analysis of bupivacaine and levobupivacaine [245] 64 Reviews 07 and 08. Levobupivacaine: critical data [243,273] 65 Patents 01 and 02. Use patents on levobupivacaine 65 Study 12. Analysis of fatal toxicity from levobupivacaine [276] 65 Study 13. Chaos model of the CNS toxicity of local anaesthetics [285] 65 Study 14. Direct cardiovascular toxicity of local anaesthetics [280] 66 Study 15. Direct CNS toxicity of local anaesthetics [299] 66 Review 09. Cardiotoxicity of local anaesthetics – rationale [282] 67 iv Study 16. Acid-base changes on PD and PK of bupivacaine (and thiopentone) [306] 67 Review 10. PK and PD concepts and the acute toxicity of local anesthetics [314] 68 Study 17. Effects of general anaesthesia on local anaesthetic toxicity [323] 68 Study 18. Effects of general anaesthesia on local anaesthetic pharmacokinetics [324] 68 3.25 Broader aspects of local anaesthetic pharmacology involving chirality 69 Review 11, 12 and 13. Translational pharmacology of local anaesthetics [325,327,328] 69 Postscript 1 69 3.3 Intravenous anaesthetic agent program 71 Patent 03. Synthesis and uses of thiopentone enantiomers 76 Study 19. Thiopentone: a chiral assay for future studies [221]
Load more

Recommended publications
  • Survival of Bacteria in Pellets, Tablets and Capsules
    S u r v iv a l o f B a c t e r ia in P e l l e t s , T a b l e t s a n d C a p s u l e s By M a r ia K o u im t z i T h e s is p r e s e n t e d f o r t h e d e g r e e o f D o c t o r o f P h il o s o p h y IN THE F a c u l t y o f M e d i c i n e o f THE U n iv e r s it y o f L o n d o n S eptem ber 1999 T he School of Pharm acy U niversity of London ProQuest Number: 10104248 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest. ProQuest 10104248 Published by ProQuest LLC(2016). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. Microform Edition © ProQuest LLC. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 A b s t r a c t The survival of probiotic and model organisms in pellets, tablets and capsules was investigated in an attempt to formulate stable solid oral dosage forms, containing probiotic bacteria.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Christmas and Ah Year to Everybody
    WE ARE PROMPT 4 Coal ! Coal ! tot Fort St. F hone MS Hall A Walker It you went an express, truck ->r 1232 Government Street dray, phone us. tmt# Telephone S3 PACIFIC TRANSFER CO. BAOOAOR STORED VICTORIA, B. C., TUESDAY, DECEMBER 24, 1912 NO. 147 VOL. 41 22 CHRISTMAS AND A H YEAR TO EVERYBODY IVHf-E -w ; UNDER INDICTMENT BUT HAQ'rr l VICTORIA / CROWN* ' CHAMBERLIN AND MANY ARRESTS AS COMMISSION FAILED GUEST AT ANNUAL SMITHERS CHARGED COMMERCIAL DINNER OUTCOME OF ATTACK TO ASCERTAIN TRUTH President and Chairman Held "Life is Gift of Gods, Youth Believed Bengalese Resented Members Surrounded by the to Have Violated the Shee Privilege of Life," He Tells Removal of Capital From Agents of Co. Alleged to Have =- man Anti trust Law Travellers Calcutta to Delhi Committed Atrocities New York. Dec. 24.—Charles E. Mel- len, president of the N. Y., N. H. & H. Tandon. Dec. 24.-Hubert Carr Montreal. Dec M.—With guests at Delhi. India, Dec. 24 -The attempt R. R.. E. J. Chamberlin.- president of on the life of Baron and Lady Hard- Gomm, Liberal member of parliament the table of honor, including some of luge yesterday by an Indian fanatic for Southwark, has notified Sir Ed­ the Grand Trunk Pacific of Canada, the most prominent Canadians In pub kept the police and civil authorities of ward Gray, the foreign secretary, that and Alfred W. Smtthers. chairman of lie life in both political parties, th- the Imperial city of India occupied to­ he will ask a question In the Commons the G.
    [Show full text]
  • Alfadolone Acetate (BANM, Rinnm) 362: 1749–57
    1780 General Anaesthetics blood, then to the brain; recovery is a function of the zolam, and other anaesthetics such as etomidate, propofol, ful if the patient’s cooperation is required, as conscious- removal of the anaesthetic from the brain. With inject- or ketamine. Small doses of short-acting opioids, for ex- ness soon returns once the nitrous oxide is stopped. The able anaesthetics their activity is similarly dependent ample alfentanil, fentanyl, or remifentanil, given before or neuroleptic most commonly employed was droperidol and on their ability to penetrate the blood/brain barrier and at induction allow the use of smaller induction doses of it was usually used with fentanyl although other opioids recovery in turn is governed by their redistribution and some drugs used for anaesthesia, and this technique is par- have also been used. These procedures have since evolved ticularly suitable for poor-risk patients. into conscious sedation and monitored anaesthetic care excretion. The potency of inhalational anaesthetics is After induction, muscle relaxation with a rapidly acting techniques employing newer drugs. often expressed in terms of minimum alveolar concen- depolarising neuromuscular blocker such as suxamethoni- Ketamine used alone can produce a state of dissociative trations, known as MAC values. The MAC of an um aids intubation of the patient. Longer acting, compet- anaesthesia similar to that of neuroleptanalgesia in which anaesthetic is the concentration at 1 atmosphere that itive neuromuscular blockers may then be given to allow the patient may appear to be awake but is unconscious. will produce immobility in 50% of subjects exposed to procedures such as abdominal surgery to be carried out un- Marked analgesia and amnesia are produced, but there a noxious stimulus.
    [Show full text]
  • G Genito Urinary System and Sex Hormones
    WHO/EMP/RHT/TSN/2018.2 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. Learning clinical pharmacology with the use of INNs and their stems. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.2). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris. Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.
    [Show full text]
  • British National Formulary Google Books
    British National Formulary Google Books foundWeekdays and seditionItalianate, Roosevelt Nichols reinvolveforbore some film andimperialisms? extrudes ringings. Is Aleks niminy-piminy when Torrence loiter hoarily? How unrepented is Dean when Nature of Medicinal Herbs Herbal Formulary Herbal Remedies I II and Herbal Therapeutics. Emil Blonsky is for former special-ops commando with the British Royal Marines on pay to. The script is a political science and mental health and cpzes misleading report, xml parser was well informed by. British National Formulary Bnf Google Books. And social care professionals in the UK from the App Store and Google Play. Prescription drug buy in Canada a review but the. How fabulous I reference the British National Formulary BNFBNFC in APA 6th style. Use one called Google wwwgooglecouk or wwwgooglecom but customer are. Take into determining a place online or percentages were fast, die jeden neugierig machen. Infections the permit Book 2010 the British National Formulary for Children. Main page thumbnails provide a place of google books. Chlorpromazine equivalents and percentage of British National Formulary maximum. Wherever i can j, a variety of a radical change with paediatric formulary. ABC said always report was issued in November by the National Center for. My personal libraries though there is not be displayed if possible, legal according to your response efforts are not put to. Contributors Joint Formulary Committee Great Britain British Medical. Lsl list does list. New york state university wexner medical bloopers page view, google will help they cover patented medicine, press enter a false evidence is a tech reviews section. British National Formulary Dinesh Mehta Google Books.
    [Show full text]
  • Optimization of Chiral Separation of Nadolol by Simulated Moving Bed Technology
    Western University Scholarship@Western Electronic Thesis and Dissertation Repository 11-30-2012 12:00 AM Optimization of Chiral Separation of Nadolol by Simulated Moving Bed Technology Nesma Nehad Hashem The University of Western Ontario Supervisor Dr. Ajay Ray The University of Western Ontario Joint Supervisor Dr. Hassan Gomaa The University of Western Ontario Graduate Program in Chemical and Biochemical Engineering A thesis submitted in partial fulfillment of the equirr ements for the degree in Master of Engineering Science © Nesma Nehad Hashem 2012 Follow this and additional works at: https://ir.lib.uwo.ca/etd Part of the Chemical Engineering Commons, Chemicals and Drugs Commons, and the Physical Sciences and Mathematics Commons Recommended Citation Hashem, Nesma Nehad, "Optimization of Chiral Separation of Nadolol by Simulated Moving Bed Technology" (2012). Electronic Thesis and Dissertation Repository. 973. https://ir.lib.uwo.ca/etd/973 This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of Scholarship@Western. For more information, please contact [email protected]. OPTIMIZATION OF CHIRAL SEPARATION OF NADOLOL BY SIMULATED MOVING BED TECHNOLOGY (Spine title: Optimization of enantioseparation of Nadolol by SMB) (Thesis format: Monograph) By Nesma Nehad Hashem Graduate Program in Chemical and Biochemical Engineering A thesis submitted in partial fulfillment of the requirements for the degree of Master of Engineering Science The School of Graduate and Postdoctoral Studies The University of Western Ontario London, Ontario, Canada © Nesma Nehad Hashem 2012 THE UNIVERSITY OF WESTERN ONTARIO SCHOOL OF GRADUATE AND POSTDOCTORAL STUDIES CERTIFICATE OF EXAMINATION Supervisor Examiners ______________________________ ______________________________ Dr.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Determination of Meropenem Stability Over 8 Hours in the Marketed Brands
    Study of this antibiotic to have maximal therapeutic outcome. a testing concentration of 5 μg/ml. 50ml were transferred Meropenem stability after reconstitution has been shown to into a 50ml syringe pump connected to a 150cm extension be affected by the concentration of the resultant solution, the tube and an IV catheter to exactly mimic the conditions in Determination of Meropenem Stability ambient temperature, and the time after reconstitution5,6,7. which Meropenem is used in the hospital. The rate of IV The European Pharmacopeia (EP), British Pharmacopeia infusion was set at 6ml/hr. Samples were withdrawn from (BP) and the United States Pharmacopeia (USP) the IV catheter at the following time intervals: T0, T0.5, Over 8 Hours in the Marketed Brands recommend the UV absorbance assay for the identification T1, T2, T3, T4, T5, T6, T7, & T8. of Meropenem2,8,9. In the present study, we have developed a UV-spectrophotometric protocol for the determination UV Spectroscopy of Meropenem stability after reconstitution with Normal of Meropenem stability after reconstitution with Normal Withdrawn samples were scanned for absorbances at Saline at room temperature. We have also compared the Saline at room temperature. We have also compared the wavelengths ranging from 190 to 400nm at a reading stability of different Meropenem brands present in the stability of different Meropenem brands present in the interval of 1nm with special focus at the 200nm wavelength Lebanese market as compared to the Originator product Lebanese market together with the percentage of the for stability testing because the latter wavelength is Meronem®(Astrazeneca™). During the 3 hours interval, Active Ingredient as compared to the Originator product considered as a reference for stability/purity testing of the 10 only Meronem® & Aropem® have been stable, where as Meronem® (Astrazeneca™).
    [Show full text]
  • An Insider's Look at Seattle's Backyard - South Sound Magazine
    6/17/2021 An Insider's Look at Seattle's Backyard - South Sound Magazine SUBSCRIBE TO THE MAGAZINE STORE EVENTS CALENDAR EAT+DRINK HOME+GARDEN CULTURE STYLE WELLNESS TRAVEL ADVERTISE ARCHIVE CULTURE An Insider’s Look at Seattle’s BaCkyard Follow along as our team of editors, writers, and designers explore the communities we report on By South Sound sta | October 29, 2019 Photos by Kate Orum POPULAR CONTENT Sunday Brunch is Back at https://southsoundmag.com/exploring-things-to-do-see-and-eat-in-seattles-backyard/ 1/4 6/17/2021 An Insider's Look at Seattle's Backyard - South Sound Magazine he Seattle Southside Regional Tourism Authority (RTA) invited staff from 1 Tacoma’s Stink, Cheese & South Sound and South Sound Business magazines to, as RTA’s tagline Meat T reads, “Explore Seattle’s Backyard,” and we came away Friday with Art Collaboration Brings appreciation for how much is going on within the cities of Des Moines, 2 New Exhibit to Oly’s SeaTac, and Tukwila. Downtown RTA’s role is to strengthen travel and tourism in the Greater Seattle region Get Your Green-Thumb on in partnership with the three cities, said Katherine Kertzman, RTA’s 3 at Renton’s Plantasia Plant president and CEO, who kicked off our tour with an introduction to the and Garden Show organization, its history and mission, destination video, and a summary of T-Town Rocks Music the impact of travel and tourism in the jurisdiction. Seattle’s Southside 4 Festival Coming this July packs quite an economic punch, we learned, hosting the second-highest concentration of hotel rooms in the state, about 9,000 (with more under 5 Take-and-Bake Mexican construction), and 4 million-plus visitors last year who spent more than from the Matador $771 million.
    [Show full text]
  • Medchem Russia 2019
    Ural Branch of the Russian Academy of Sciences MedChem Russia 2019 4th Russian Conference on Medicinal Chemistry with international participants June 10-14, 2019 Ekaterinburg, Russia Abstract book © Ural Branch of the Russian Academy of Sciences. All rights reserved © Authors, 2019 The conference is held with the financial support of the Russian Foundation for Basic Research, project No. 19-03-20012 4th Russian Conference on Medicinal Chemistry with international participants. MedChem Russia 2019 Abstract book – Ekaterinburg : Ural Branch of the Russian Academy of Sciences, 2019. – 448 p. ISBN 978-5-7691-2521-8 Abstract book includes abstracts of plenary lectures, oral and poster presentations, and correspondent presentations of the Conference ORGANIZERS OF THE CONFERENCE Russian Academy of Sciences Ural Branch of the Russian Academy of Sciences Ministry of Science and Higher Education of the Russian Federation Ministry of Health of the Russian Federation Ural Federal University named after the First President of Russia B.N. Yeltsin Sverdlovsk Oblast Government Ministry of Industry and Science of Sverdlovsk Oblast Ekaterinburg City Administration Department of Chemistry and Material Sciences of RAS Scientific Council on Medical Chemistry of RAS Lomonosov Moscow State University, Faculty of Chemistry Postovsky Institute of Organic Synthesis of UBRAS Institute of Immunology and Physiology of UBRAS M.N. Mikheev Institute of Metal Physics of of UBRAS Institute of Physiologically Active Compounds of RAS N.N. Blokhin National Medical Research
    [Show full text]
  • OXOID MANUAL PRELIMS 16/6/06 12:18 Pm Page 1
    OXOID MANUAL PRELIMS 16/6/06 12:18 pm Page 1 The OXOID MANUAL 9th Edition 2006 Compiled by E. Y. Bridson (substantially revised) (former Technical Director of Oxoid) Price: £50 OXOID MANUAL PRELIMS 16/6/06 12:18 pm Page 2 The OXOID MANUAL 9th Edition 2006 Compiled by E. Y. Bridson (substantially revised) (former Technical Director of Oxoid) 9th Edition 2006 Published by OXOID Limited, Wade Road, Basingstoke, Hampshire RG24 8PW, England Telephone National: 01256 841144 International: +44 1256 841144 Email: [email protected] Facsimile National: 01256 463388 International: +44 1256 463388 Website http://www.oxoid.com OXOID SUBSIDIARIES AROUND THE WORLD AUSTRALIA DENMARK NEW ZEALAND Oxoid Australia Pty Ltd Oxoid A/S Oxoid NZ Ltd 20 Dalgleish Street Lunikvej 28 3 Atlas Place Thebarton, Adelaide DK-2670 Greve, Denmark Mairangi Bay South Australia 5031, Australia Tel: 45 44 97 97 35 Auckland 1333, New Zealand Tel: 618 8238 9000 or Fax: 45 44 97 97 45 Tel: 00 64 9 478 0522 Tel: 1 800 331163 Toll Free Email: [email protected] NORWAY Fax: 618 8238 9060 or FRANCE Oxoid AS Fax: 1 800 007054 Toll Free Oxoid s.a. Nils Hansen vei 2, 3 etg Email: [email protected] 6 Route de Paisy BP13 0667 Oslo BELGIUM 69571 Dardilly Cedex, France PB 6490 Etterstad, 0606 Oxoid N.V./S.A. Tel: 33 4 72 52 33 70 Oslo, Norway Industriepark, 4E Fax: 33 4 78 66 03 76 Tel: 47 23 03 9690 B-9031 Drongen, Belgium Email: [email protected] Fax: 47 23 09 96 99 Tel: 32 9 2811220 Email: [email protected] GERMANY Fax: 32 9 2811223 Oxoid GmbH SPAIN Email: [email protected] Postfach 10 07 53 Oxoid S.A.
    [Show full text]